Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer

NCT05385185 is registered in ClinicalTrials.gov with Hebei Medical University as lead sponsor.

NCT NCT05385185
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05385185 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer
Lead sponsor
Hebei Medical University
Phase
Phase 2
Overall status
Unknown status
Start date
May 1, 2022
Completion date
December 3, 2024
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endostatin, immune checkpoint inhibitor, leptomeningeal metastasis